Interpace Biosciences (OTCMKTS:IDXG) Posts Quarterly Earnings Results

Interpace Biosciences (OTCMKTS:IDXG) released its quarterly earnings data on Monday. The business services provider reported $0.01 earnings per share for the quarter, Zacks reports. The company had revenue of $9.13 million during the quarter. Interpace Biosciences had a net margin of 67.64% and a return on equity of 165.19%.

Interpace Biosciences Price Performance

Shares of OTCMKTS:IDXG opened at $1.67 on Wednesday. The firm has a 50 day moving average of $1.61 and a 200 day moving average of $1.77. The company has a market capitalization of $7.39 million, a price-to-earnings ratio of -33.38 and a beta of 0.61. Interpace Biosciences has a 52 week low of $0.77 and a 52 week high of $2.40.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.